Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: A population-based study

S. Y. Yang, Yea-Huei Kao, M. Y. Chong, Y. H. Yang, W. H. Chang, C. S. Lai

研究成果: Article

39 引文 斯高帕斯(Scopus)

摘要

To compare the prevalence of extrapyramidal syndrome (EPS) between the first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs), the co-prescribing rate of anti-Parkinson drugs (APDs) of each antipsychotic drug was analyzed using population database. Fourteen antipsychotics had been prescribed during the 5-year study period. Among the SGAs, quetiapine had the lowest crude co-prescribing rate of APDs (27.09%), whereas risperidone had the highest rate (66.50%). Among the FGAs, thioridazine and loxapine had the lowest (60.99%) and highest rates (96.35%), respectively. The rankings of the co-prescribing rate of APDs among antipsychotics, in increasing order, were quetiapine, clozapine, olanzapine, thioridazine, zotepine, chlorpromazine, risperidone, sulpiride, clotiapine, flupentixol, haloperidol, zuclopentixol, trifluoperazine, and loxapine. The results indicate that the risk of EPS appears to be lower in SGAs than in FGAs; however, the considerably high rate of EPS in some of the newer generation of antipsychotics warrants clinical attention.

原文English
頁(從 - 到)586-594
頁數9
期刊Clinical Pharmacology and Therapeutics
81
發行號4
DOIs
出版狀態Published - 2007 五月 10

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

指紋 深入研究「Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: A population-based study」主題。共同形成了獨特的指紋。

  • 引用此